60
61
2. Penelitian lebih lanjut untuk mempelajari peran reseptor hormonal dan penanda biologis lainnya pada tingkat molekuler atau genetik sangat diperlukan untuk menentukan mekanisme yang terjadi.
3. Evaluasi lebih lanjut dari penggunaan hormon eksogen pada wanita dengan meningioma dalam studi yang lebih besar diperlukan dengan perhatian khusus pada komposisi hormon (estrogen dan/atau progesteron), durasi dan usia saat menggunakan kontrasepsi hormonal serta subkelompok meningioma yang ditentukan oleh ekspresi reseptor tumor.
62
DAFTAR PUSTAKA
1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, et al. CBTRUS statistical report:
Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17: 1-62.
2. Westphal M, et al. Neuro-Oncology of CNS Tumors. Berlin, Heidelberg, New York:
Springer; 2006.
3. Ramamurthi and Tandon’s. Manual of Neurosurgery. First edition. New Delhi: Jaypee Brother’s Medical Publishers; 2014.
4. Pamir MN, Black P, Fahlbush RF. Meningiomas. A Comprehensive Text. Saunders Elsevier; 2010.
5. Almefty R., Haddad G. F., Al-Mefty O. Meningiomas (7th ed.). Youmans and Winn Neurological Surgery, Elsevier Inc., USA. 2017; 1107–1132
6. Doyle MD, L. A., and Hornick MD, J. L.: Epithelioid and epithelial-like Tumors (2nd ed.), in Practical soft tissue pathology: a diagnostic approach, Elsevier Inc., USA.
2019;165–208
7. Holleczek B, Zampella D, Urbschat S, Sahm F, Deimling A. Incidence, mortality and outcome of meningiomas: A population-based study from Germany. Cancer Epidemiology. 2019;62.p1-8.
8. McKee, S. P., Yang, A., Gray, M., Zeiger, J., Bederson, J. B., Govindaraj, S., Iloreta, A. M. C., and Shrivastaca, R. K.: Intracranial meningioma surgery: value-based care determinants in New York State, 1995-2015, World Neurosurgery 2018;118, 731–
744.
9. Benson VS, Pirie K, Green J, Casabonne D, Beral V. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 2008;99:185–190.
10. Supartoto, A., Mahayana, I. T., and Christine, R. N.: Exposure to Exogenous Female Sex Hormones is Associated with Increased Risk of Orbito-Cranial Meningioma in Females: A Case-Control Study, International Journal of Ophthalmic Pathology, 2016;5(3). https://doi.org/10.4172/2324-8599.1000183
11. Wahyuhadi, J., Heryani, D., and Basuki, H.: Risk of meningioma associated with exposure of hormonal contraception . A case control study 2018;26(1), 36–41.
12. Traylor JI, Kuo JS. Meningiomas: Neurosurgical Conditions and Treatments.
American Association of Neurological Surgeons. Vancouver; 2020.
13. Almefty R, Haddad GF, Al-Mefty O. Meningiomas: An overview (7th ed.). Youmans and Winn Neurological Surgery, Elsevier Inc., USA. 2011; 1107–1132.
14. Cancer, I. A. WHO Classification of Tumours of the Central Nervous System (4th ed.), WHO Press, France. 2007; 163-184.
15. Bowling, B., and Franzco. Orbit (8th ed.). Kanski’s clinical ophthalmology, Elsevier Inc., USA. 2016: 77–117.
16. Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97–109.
17. Aman RA, Soenarya MF, Andriani R, Anindhita T, Munandar A, dkk. Pedoman Nasional Pelayanan Kedokteran Tumor Otak. Kemenkes RI. 2017;19-23.
18. Wiemels J, Wrensch M, Claus E. Epidemiology and etiology of meningioma. J Neurooncol. 2010; 99(3):301-314.
19. Cea-Soriano L, Wallander MA, Rodriguez G. Epidemiology of Meningioma in the United Kingdom. Neuroepidemiology. 2012;39(1); 27-3.
63
20. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, et al. Meningiomas:
knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg October 24, 2014.
21. Al-Hadidy AM, Maani WS, Mahafza WS, Al-Najar MS, Al-Nadii MM. Intracranial meningioma. J Med J 2007; Vol. 41 (1): 37- 51.
22. Petrilli AM, Fernandez-Valle C (2016) Role of Merlin/NF2 inactivation in tumor biology. Oncogene 35: 537-554.
23. Amatya VJ, Takeshima Y, Sugiyama K, et al.: Immunohistochemical Study of Ki-67 (MIB-1), p53 protein, p21W AF1 and p27KIP1 Expression in Benign, Atypical and Anaplastic Meningiomas. Hum Pathol 2001; 32: 970–975.
24. Roessler K, Gattenbauer B, Kitz K: Topoisomerase II Alpha as a Reliable Proliferation Marker in Meningiomas. Neurol Res 2002; 24: 241–244.
25. Konstantinidou AE, Korkolopoulou P , Kavantzas N, et al.: Mitosin, a Novel Marker of Cell Proliferation and Early Recurrence in Intracranial Meningiomas. Histol Histopathol 2003;18: 67–74.
26. Strik HM, Strobelt I, Pietsch-Brietfeld B,et al.: The Impact of Progesterone Receptor Expression on Relapse in the Long-term Clinical Course of 93 Benign Meningiomas.
In Vivo 2002; 16: 265– 270.
27. Nagashima G, Asai J, Suzuki R, et al.: Different Distribution of c-myc and MIB-1 Positive Cells in Malignant Meningiomas with Reference to TGFs, PDGF and PgR Expression. Brain Tumor Pathol 2001; 18:1–5.
28. Blankenstein MA, Verheijen FM, Jacobs JM, et al.: Occurrence, Regulation and Significance of Progesterone Receptors in Human Meningioma. Steroids 2002; 65:
795–800.
29. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and Estrogen Receptors in Meningiomas: Prognostic considerations. J Neurosurg 1997; 86: 113–120.
30. Meewes C, Bohuslavizki KH, Krisch B, Held-Feindt J, Henze E, Clausen M.
Molecular Biologic and Scintigraphic Analyses of Somatostatin Receptor-negative Meningiomas. J. Nucl. Med. 2001; 42(9):1338-45.
31. Schulz S, Pauli SU, Schulz S, et al.: Immunohistochemical Determination of Five Somatostatin Receptors in Meningioma Reveals Frequent Overexpression of Somatostatin Receptor Subtype sst2A. Clin Cancer Res 2000; 6:1865–1874.
32. Preston DL, Ron E, Yonehara S, Kobuke T, Fujii H, Kishikawa M, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst. 2002;94:1555–1563.
33. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207–1215.
34. Lahkola A, Tokola K, Auvinen A. Meta-analysis of mobile phone use and intracranial tumors. Scand J Work Environ Health 2006;32(3):171–177.
35. Phillips LE, Koepsell TD, van Belle G, Kukull WA, Gehrels JA, Longstreth WT Jr.
History of head trauma and risk of intracranial meningioma: population-based case–
control study. Neurology. 2002;58:1849–1852.
36. Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M.
Family and Personal Medical History and Risk of Meningioma. J Neurosurg. 2011 Dec;115(6):1072-7.
37. Malmer B, Henriksson R, Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer 2003;106:260–263.
38. Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granstrom C. Familial risks in
64
nervous-system tumours: a histology-specific analysis from Sweden and Norway.
Lancet Oncol 2009;10: 481–488.
39. Taghipour M, Rakei SM, Monabati A, Nahavandi-Nejad M. The role of estrogen and progesterone receptors in grading of the malignancy of meningioma. IRCMJ 2007;
9(1):17-21.
40. Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, et al. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013;118: 649-656.
41. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99: 848-853.
42. Vadivelu S, Sharer L, Schulder M. Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg 2010;112:920–
924.
43. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008;26:279–282.
44. Custer B, Longstreth WT, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 2006;6: 152.
45. Michaud DS, Gallo V, Schlehofer B, Tjønneland A, Olsen A, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev 2010;19: 2562-2569.
46. Claus EB, Park PJ, Carroll R, Chan J, Black PM. Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res 2008;68:314–
322.
47. Wernicke AG, Dicker AP, Whiton A, Ivanidze J, Hyslop T, et al. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.
Radiation Oncology 2010, 5:46.
48. Choong KH, Jin CH, Jae KM. Correlation of granulin expression in intracranial meningiomas to clinical parameters. Experimental and Therapeutic Medicine.
2010;1:493-496.
49. Johnson MD, O’Conell MJ, Pilcher W, Reeder JE. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg. 2010 May;112(5):934-9.
50. Pfister C, Pfrommer H, Tatagiba MS, Roser F. Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. Br J Cancer. 2012 Nov 6; 107(10): 1702–1713.
51. Lee JH. Meningioma: Diagnosis, Treatment, and Outcome. Springer. Cleveland.
2009;101-131.
52. Osborn AJ, et al. Diagnostic Imaging. Brain. Amirsys, 1st Ed. 2004:II-4.
53. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas:
A review. Neurosurgery 2005;57:538-50.
54. Ferraro DJ. A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas. Radiat Oncol. 2014 Jan 27;9:38.
55. Moazzam AA, Wagle N, Zada G. Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus. 2013 Dec;35(6):E18.
56. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006; 5: 1045–54.
57. Starbird E, Norton M, Marcus R. Investing in family planning: key to achieving the sustainable development goals. Glob Health Sci Pract. 2016;4(2):191-210.
65
58. United Nations, Department of Economic and Social Affairs, Population Division.
World Family Planning 2017 - Highlights (ST/ESA/SER.A/414).
59. Leon S, Philip D. "Oral contraception". A clinical guide for contraception. 5th ed.
Philadelphia: Lippincott Williams & Wilkins. 2011;19–152.
60. Nelson AL, Willard Jr. C, Deborah K, Michael S. Contraceptive technology (20th revised ed.). New York: Ardent Media. 2012;249–341.
61. Anna G. "Contraception". In Jameson, J. Larry; De Groot, Leslie J.
(eds.). Endocrinology (6th ed.). Philadelphia: Saunders Elsevier. 2010;2417–2427.
62. Nelson, Anita L.; Cwiak, Carrie (2011). "Combined oral contraceptives (COCs)". In Hatcher, Robert A.; Trussell, James;
63. Levin, Ellis R.; Hammes, Stephen R. (2011). "Estrogens and progestins". In Brunton, Laurence L.; Chabner, Bruce A.; Knollmann, Björn C. (eds.). Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill Medical.
pp. 1163–1194.
64. Camacho-Arroyo I, Hansberg-Pastor V, Vázquez-Martínez ER, Cerbón M.
Mechanism of Progesterone Action in the Brain. Hormones, Brain and Behavior.
2017;181–214.
65. Cromer BA, Scholes D, Berenson A, et al. Depot medroxy-progesterone acetate and bone mineral density in adolescents—the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296–301.
66. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002;
13:581–587.
67. Bernauer S, Wehling M, Gerdes D, Falkenstein E. The human membrane progesterone receptor gene: genomic structure and promoter analysis DNA Sequence.
2001;(12):13–25.
68. Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues:
regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal. 2009; 7: e009.
69. Leonhardt SA, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids. 2003 Nov;68(10-13):761-70.
70. Fakhrjou A, Meshkini A, Shadrvan S. Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. Pak J Biol Sci. 2012 Jun 1;15(11):530-5.
71. Shayanfar N, Mashayekh M, Mohammadpour M. Expression of Progestrone Receptor and Proliferative Marker ki 67 in Various Grades of Meningioma. Acta Medica Iranica, Vol. 48, No. 3:2010;142-147.
72. Omulecka, et al. Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol 2006;44(2): 111-115.
73. Supartoto et al. Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females. Front. Oncol.2019; 8:651.
74. Butts CL, Shukair SA, Duncan KM, Bowers E, Horn C, Belyavskaya E, et al.
Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. Int Immunol. 2007;19:287–96.
75. Garcia-Ruíz G, Flores-Espinosa P, Preciado-Martínez E, Bermejo-Martínez L, Espejel-Nuñez A, Estrada-Gutierrez G, et al. In vitro progesterone modulation on bacterial endotoxin-induced production of IL-1β, TNFα, IL-6, IL-8, IL-10, MIP-1α, and MMP-9 in pre-labor human term placenta. Rep Biol Endocrinol. 2015;13:115.
66 LAMPIRAN 1. KUESIONER WAWANCARA
Nama :
Alamat :
Tanggal lahir/Usia :
Pendidikan terakhir :
Pekerjaan :
Penghasilan/bulan :
Usia menstruasi pertama kali : a. < 12 tahun
b. 12-15 tahun c. > 15 tahun
Siklus menstruasi :
a. Teratur/28 hari
b. Tidak teratur/tidak 28 hari Jenis kontrasepsi hormonal :
a. Progestogen tunggal
b. Kombinasi (estrogen + progesteron) Durasi paparan kontrasepsi hormonal :
a. < 5 tahun b. 5-10 tahun c. > 10 tahun
67
LAMPIRAN 2. LEMBAR PERSETUJUAN SETELAH PENJELASAN
PERSETUJUAN SETELAH PENJELASAN (PSP) UNTUK IKUT SERTA DALAM PENELITIAN (INFORMED CONSENT)
Saya telah membaca atau memperoleh penjelasan, sepenuhnya menyadari, mengerti, dan memahami tentang tujuan, manfaat, dan risiko yang mungkin timbul dalam penelitian, serta telah diberi kesempatan untuk bertanya dan telah dijawab dengan memuaskan, juga sewaktu-waktu dapat mengundurkan diri dari keikut sertaannya, maka saya setuju/tidak setuju*) ikut dalam penelitian ini, yang berjudul:
” FAKTOR RISIKO MENINGIOMA ORBITOKRANIAL PADA WANITA PENGGUNA KONTRASEPSI HORMONAL DI PUSAT MATA NASIONAL RUMAH SAKIT MATA CICENDO
BANDUNG”
Saya dengan sukarela memilih untuk ikut serta dalam penelitian ini tanpa tekanan/paksaan siapapun. Saya akan diberikan salinan lembar penjelasan dan formulir persetujuan yang telah saya tandatangani untuk arsip saya.
Saya setuju:
Ya/Tidak*)
*) coret yang tidak perlu
Tgl.:
Tanda tangan (bila tidak bisa dapat digunakan cap jempol)
Nama Peserta:
Usia:
Alamat:
Nama Peneliti:
dr. Vina Karina Apriyani Nama Saksi:
68 LAMPIRAN 3. LEMBAR PERSETUJUAN ETIK
69
LAMPIRAN 4. TABEL DATA PASIEN
No. No.
RM Nama
Usia Pendidikan terakhir Pekerjaan Pendapatan Keluarga per
bulan
Anamnesis CT-scan orbita
kepala Riwayat KB hormonal Status Reproduksi
30-39
40-49
50-60 SD SMP SMA D3/S1 IRT Wirausaha Pegawai <1.800.000 >1.800.000 Sejak Kombinasi Progestogen
tunggal Menarche Siklus
haid Hasil
1 797245 Narsadem binti Bonin
40
5-10thn
< 12thn teratur MENINGIOMA
2 797511 Chistini binti Sastro
49 >
10thn
< 12thn teratur MENINGIOMA
3 798117 Saroh binti Eri
47 >
10thn
> 15thn tidak MENINGIOMA
4 798946 Tri Purwandari
44
5-10thn
< 12thn teratur MENINGIOMA 5 799948 Awang
binti Acep 52 <
5thn > 15thn teratur BUKAN
6 800977 Nyai Juriah 49 >
10thn
12-15thn teratur MENINGIOMA
7 801026 Lomrah binti Pardi
44
5-10thn
> 15thn teratur BUKAN
8 803975 Anisah binti Somantri
54 <
5thn
> 15thn teratur BUKAN
9 804819 Sunarti binti Rusmin
48 >
10thn
12-15thn tidak MENINGIOMA
10 805800 Neng
Unayah 51 >
10thn 12-15thn teratur MENINGIOMA
11 806619 Rupini binti Suari
57 >
10thn
12-15thn teratur MENINGIOMA
12 806850 Kanem binti Kamblan
47 >
10thn
12-15thn teratur MENINGIOMA
13 807026 Tumijah binti Sandirja
43 >
10thn 12-15thn teratur MENINGIOMA
70
14 807076 Eti binti Amsin
36 >
10thn
12-15thn teratur MENINGIOMA
15 807558 Karwati binti Encang
45 >
10thn
12-15thn teratur MENINGIOMA
16 807919 Emay binti Tasum
40
5-10thn
< 12thn teratur MENINGIOMA
17 808539 Emih binti Nerin
45 >
10thn
12-15thn teratur MENINGIOMA
18 808758 Rojiah binti Sarhindi
48 <
5thn
12-15thn teratur MENINGIOMA
19 809658 Yati Ayati 44 >
10thn
12-15thn teratur MENINGIOMA
20 811301 Yuyu Yuliasari
45 <
5thn
> 15thn tidak BUKAN
21 812131 Ketut Suplin
42 >
10thn
12-15thn teratur MENINGIOMA
22 813831 Yulia binti Iwan
37 >
10thn
< 12thn teratur MENINGIOMA
23 814626 Iim binti Mahmudin
47 >
10thn
< 12thn teratur MENINGIOMA
24 815832 Idah Wahidah
41
5-10thn
> 15thn tidak BUKAN
25 817041 Lilis Gustinah
48
5-10thn
12-15thn teratur MENINGIOMA
26 818291 Tarsih binti Martadikra
53 >
10thn
< 12thn teratur MENINGIOMA
27 574286 Sukarti binti Uba
45
5-10thn
12-15thn teratur MENINGIOMA
28 601480 Eti Hayati 52 >
10thn 12-15thn tidak MENINGIOMA
29 822110 Neneng Supriati
57 >
10thn
12-15thn teratur MENINGIOMA
30 822438 Sunarmi binti Jokasmo
51 <
5thn
12-15thn tidak MENINGIOMA
71
31 823466 Neulis Siti Holipah
49 >
10thn
12-15thn teratur MENINGIOMA
32 823488 Tuti Sulastri
46
5-10thn
12-15thn tidak MENINGIOMA
33 823681 Ai
Resmiati 45 >
10thn 12-15thn teratur MENINGIOMA
34 823685 Suherti binti Dasmin
45 >
10thn
12-15thn teratur MENINGIOMA
35 820521 Reni Heryantini
45 >
10thn
12-15thn teratur MENINGIOMA
36 826539 Eros Rostiana
34
5-10thn
> 15thn tidak BUKAN
37 826681 Siti Rohati 45 >
10thn 12-15thn teratur MENINGIOMA
38 827898 Siti Julaeha 47 <
5thn
12-15thn teratur BUKAN
39 829020 Sudarmi binti Saidi
41 >
10thn
12-15thn teratur MENINGIOMA
40 830303 Ela binti Ana
36 >
10thn
< 12thn teratur MENINGIOMA
41 832832 Enung Ilyas
47 >
10thn
12-15thn teratur MENINGIOMA
42 837281 Kartini binti Obon
39 >
10thn
12-15thn teratur MENINGIOMA
43 839730 Rusinah binti Kamar
52 >
10thn
12-15thn teratur MENINGIOMA
44 838901 Euis Nurhayati
57 <
5thn
12-15thn teratur BUKAN
45 839555 Poniyah binti Nasri
45 >
10thn
> 15thn tidak MENINGIOMA
46 840509 Tarsinah binti Sokim
45 >
10thn
> 15thn tidak MENINGIOMA
47 840811 Enceu Hamidah
50 <
5thn
12-15thn teratur BUKAN
72
48 841789 Yani Suryani
45 >
10thn
> 15thn tidak MENINGIOMA
49 841871 Amsinah binti Aswi
38
5-10thn
> 15thn tidak MENINGIOMA
50 842012 Yeni Suryani
45 >
10thn
> 15thn teratur MENINGIOMA
51 842109 Yayu Susilawati
31
5-10thn
> 15thn teratur BUKAN 52 843429 Winda
Wiandini
47 >
10thn
> 15thn tidak MENINGIOMA
53 843359 Saripah binti Kasan
48 >
10thn
12-15thn teratur MENINGIOMA
54 847266 Tri Indah P 47 >
10thn
12-15thn teratur MENINGIOMA
55 848675 Een binti
Aleh 49 >
10thn 12-15thn tidak MENINGIOMA
56 850314 Rostini binti Yaya
47 >
10thn
12-15thn teratur MENINGIOMA
57 850775 Sarsiah binti Maman
49 >
10thn
< 12thn teratur MENINGIOMA
58 851596 Iis Sapitri 47 >
10thn
< 12thn teratur MENINGIOMA
59 851730 Yuyun
binti Ita 38 >
10thn 12-15 thn teratur MENINGIOMA
60 852903 Teti Sumiati
52 >
10thn
12-15thn teratur MENINGIOMA
61 852993 Oting Setiawati
46 >
10thn
< 12thn teratur MENINGIOMA
62 854016 Juju
Juariyah 51 >
10thn < 12thn teratur MENINGIOMA
63 854679 Nenih binti Ujang
41 <
5thn
12-15thn teratur MENINGIOMA
64 854649 Titih Khotimah
45 >
10thn
12-15 thn teratur MENINGIOMA
73
65 856069 Saminah binti Kasno
44 >
10thn
12-15thn teratur MENINGIOMA
66 856699 Jinar Nuryuninda
49 >
10thn
12-15thn teratur MENINGIOMA
67 861420 Narni binti Salim
42 >
10thn
12-15thn teratur MENINGIOMA
68 863776 Ina Marlina 41 >
10thn
< 12thn teratur MENINGIOMA
69 864449 Titing binti H. Zakaria
47
5-10thn
< 12thn tidak MENINGIOMA
70 865855 Nialawati binti Ahmid
48 >
10thn
< 12thn tidak MENINGIOMA
71 866819 Marlina binti Acun
42 >
10thn
< 12thn tidak MENINGIOMA
72 868186 Yeti Karwati
54 >
10thn
12-15thn teratur MENINGIOMA
73 866350 Cucu binti Ujang
42 >
10thn
12-15thn teratur MENINGIOMA
74 869802 Yati binti Oman
42 >
10thn
12-15thn teratur MENINGIOMA
75 870580 Neneng Rohanah
46 >
10thn
> 15thn teratur BUKAN 76 871799 Sarmi binti
Imun 37
5-10thn < 12thn teratur MENINGIOMA
77 874549 Eros binti
Dori 47 >
10thn < 12thn teratur MENINGIOMA
78 875009 Ai Kartika 45 >
10thn
< 12thn tidak MENINGIOMA
79 875699 Rodiah
binti Sadria 42 >
10thn 12-15thn teratur MENINGIOMA
80 886976 Solihah binti Iwa
44 >
10thn
12-15thn teratur MENINGIOMA
81 888259 Susilawati binti Ma'mun
39
5-10thn
12-15thn teratur MENINGIOMA
74
DAFTAR RIWAYAT HIDUP
Nama : Vina Karina Apriyani
NPM : 131221170001
Tempat & Tanggal Lahir : Bandar Lampung, 23 April 1984
Alamat : Jl. Pondok Jaya IV no. 4B Mampang Jakarta Selatan Nama Orang tua : Yan Martham, SE (alm.), Nining K. Rachman, SE Nama Suami : Rhino Prayudhi, SE
Nama Anak : Ghazi Zabran Nabhani, Gibran Zavier Nadhifa
Riwayat Pendidikan Formal:
1. SDN Tugu X Depok (1990-1996) 2. SMPN 102 Cijantung (1996-1999) 3. SMAN 14 Cawang (1999-2002)
4. Program Studi Sarjana Kedokteran, Fakultas Kedokteran Universitas Pelita Harapan (2002-2006)
5. Program Studi Profesi Dokter, Fakultas Kedokteran Universitas Pelita Harapan (2006-2008)
6. Program Pendidikan Dokter Spesialis I, Ilmu Kesehatan Mata, Fakultas Kedokteran Universitas Padjajaran – Pusat Mata Nasional Rumah Sakit Mata Cicendo, Bandung (2017-2021).
75
Pengalaman Kerja:
1. Dokter Umum Klinik CBC, Jakarta (2008-2009)
2. Staf Direktorat Jenderal P2PL Kementerian Kesehatan RI (2009-2013) 3. Dokter Umum RS Pusat Otak Nasional, Kemenkes RI, Jakarta (2013-2017)
Pengalaman Organisasi:
1. Anggota Community Outreach Team for Asian Medical Students Association (AMSA) Indonesia, Fakultas Kedokteran Universitan Pelita Harapan (2004-2006).
2. Panitia the 1st Scientific Meeting Updates in Neurology, Jakarta tahun 2014 divisi Registration and Acomodation.
3. Panitia the 2nd Scientific Meeting Updates in Neurology, Bandung tahun 2015 divisi Registration and Acomodation.
4. Panitia the 3rd Scientific Meeting Updates in Neurology, Jakarta tahun 2016 divisi Social Program.
5. Panitia the 1st Cicendo International Meeting (CIOM), Bandung tahun 2019 divisi Publikasi dan Dokumentasi dan Liaison Officer (LO).
Penelitian/Penulisan Karya Ilmiah:
1. Hubungan antara Densitas Mineral Tulang dengan Kadar Estradiol dalam Darah pada Wanita Usia Menopause di Kecamatan Balaraja, Banten (2006).
2. Immediate versus Delayed Vitrectomy for the Management of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy (2019).